Skip to main content
. Author manuscript; available in PMC: 2020 Sep 29.
Published in final edited form as: Clin Cancer Res. 2016 Jun 15;22(24):6192–6203. doi: 10.1158/1078-0432.CCR-15-2792

Figure 5: Mcl-1 expression is required in ATC cells for combinatorial efficacy of the sorafenib (S) and quinacrine (Q).

Figure 5:

(A) Western blot assessment of the efficacy of small interfering RNA (siRNA)-dependent targeting of Mcl-1 expression in 8505C cells. (B) CellTiter-Glo® cell survival assay. Sorafenib (C) and quinacrine (D) dose-response curves in 8505C cells following siRNA mediated targeting of Mcl-1. The X-axis are shown as log scale. (E) The observed IC50-values following S and Q treatment with and without Mcl-1-targeting. Isobolograms for 8505C cells treated with various effective S and Q concentrations (ICS80/Q30, ICS80/Q50 and ICS80/Q60) in the presence (F) and absence (G) of Mcl-1 knock-down.